Trials / Completed
CompletedNCT01959035
Aripiprazole Once-monthly in Patients With Schizophrenia
Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
To obtain information on the safety, tolerability and effectiveness of aripiprazole once-monthly in a manner consistent with its intended use in everyday clinical practice in patients with schizophrenia who completed Study 14724A / NCT01795547.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aripiprazole once-monthly | 400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2015-03-01
- Completion
- 2015-03-01
- First posted
- 2013-10-09
- Last updated
- 2017-03-17
- Results posted
- 2016-05-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01959035. Inclusion in this directory is not an endorsement.